Document is current

Article History

Accepted: 28 May 2025

First Online: 26 June 2025

Declarations

:

: Funding for conducting the study and preparation of the manuscript was provided by Viatris.

: Sven Hartmann, Emma Bennett-Huntley, and Amy Todd are employees of Viatris. J. Enrique Domínguez-Muñoz received a research grant from Viatris and worked as a paid consultant/speaker for Viatris, Abbott, AbbVie, and Boston Scientific. Authors have no other competing interests to declare. Viatris (formerly Mylan) is the marketing authorization holder and distributor of Creon in Europe and Canada. Views in this manuscript are not necessarily those of Viatris.

: The authors declare that the data supporting the findings of this study are available within the paper and its supplementary information files. 

: Not applicable as this is an in-vitro study.

: Not applicable as this is an in-vitro study.

: Not applicable.

: Not applicable.

: SH contributed to conception, study design, execution, acquisition of data, analysis, and interpretation, drafting, revising, and reviewing the manuscript. JR contributed to conception, analysis, and interpretation, revising, and reviewing the manuscript. AT contributed to conception, study design, execution, acquisition of data, analysis, and interpretation. EBH contributed to conception, study design, execution, acquisition of data, analysis, and interpretation. JEDM contributed to conception, analysis, and interpretation, revising, and reviewing the manuscript. All authors have read and approved the final version, agreed on the journal to which the article has been submitted and agree to be accountable for all aspects of the work.